These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

152 related items for PubMed ID: 11801765

  • 1. Combined use of prostate-specific antigen derivatives decreases the number of unnecessary biopsies to detect prostate cancer.
    Ozen H, Aygün C, Ergen A, Sözen S, Aki FT, Uygur MC.
    Am J Clin Oncol; 2001 Dec; 24(6):610-3. PubMed ID: 11801765
    [Abstract] [Full Text] [Related]

  • 2. Prostate specific antigen density of the transition zone for early detection of prostate cancer.
    Djavan B, Zlotta AR, Byttebier G, Shariat S, Omar M, Schulman CC, Marberger M.
    J Urol; 1998 Aug; 160(2):411-8; discussion 418-9. PubMed ID: 9679889
    [Abstract] [Full Text] [Related]

  • 3. The value of percent free prostate specific antigen, prostate specific antigen density of the whole prostate and of the transition zone in Turkish men.
    Akduman B, Alkibay T, Tuncel A, Bozkirli I.
    Can J Urol; 2000 Oct; 7(5):1104-9. PubMed ID: 11114873
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. [Value of prostate-specific antigen density and transitional-zone prostate-specific antigen density in the diagnosis of prostate cancer].
    Martínez Jabaloyas JM, García Morata F, Villamón Fort R, Pastor Hernández F, Gil Salom M, García Sisamón F.
    Actas Urol Esp; 2003 Jun; 27(6):442-9. PubMed ID: 12918151
    [Abstract] [Full Text] [Related]

  • 7. Percent free prostate specific antigen in the total prostate specific antigen 2 to 4 ng./ml. range does not substantially increase the number of biopsies needed to detect clinically significant prostate cancer compared to the 4 to 10 ng./ml. range.
    Haese A, Dworschack RT, Partin AW.
    J Urol; 2002 Aug; 168(2):504-8. PubMed ID: 12131298
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Clinical usefulness of free PSA in early detection of prostate cancer.
    Luboldt HJ, Swoboda A, Börgermann C, Fornara P, Rübben H, Early Detection Project Group of the German Society of Urology.
    Onkologie; 2001 Feb; 24(1):33-7. PubMed ID: 11441278
    [Abstract] [Full Text] [Related]

  • 11. The value of endorectal MRI in the early diagnosis of prostate cancer.
    Comet-Batlle J, Vilanova-Busquets JC, Saladié-Roig JM, Gelabert-Mas A, Barceló-Vidal C.
    Eur Urol; 2003 Aug; 44(2):201-7; discussion 207-8. PubMed ID: 12875939
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Normal range prostate-specific antigen versus age-specific prostate-specific antigen in screening prostate adenocarcinoma.
    el-Galley RE, Petros JA, Sanders WH, Keane TE, Galloway NT, Cooner WH, Graham SD.
    Urology; 1995 Aug; 46(2):200-4. PubMed ID: 7542822
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Prospective evaluation of prostate specific antigen (PSA), PSA density, free-to-total PSA ratio and a new formula (prostate malignancy index) for detecting prostate cancer and preventing negative biopsies in patients with normal rectal examinations and intermediate PSA levels.
    Dinçel C, Caşkurlu T, Taşçi AI, Cek M, Sevin G, Fazlioğlu A.
    Int Urol Nephrol; 1999 Aug; 31(4):497-509. PubMed ID: 10668945
    [Abstract] [Full Text] [Related]

  • 16. Determination of the percentage of free prostate-specific antigen helps to avoid unnecessary biopsies in men with normal rectal examinations and total prostate-specific antigen of 4-10 ng/ml.
    Martínez-Piñeiro L, Tabernero A, Contreras T, Madero R, Lozano D, López-Tello J, Alonso-Dorrego JM, Picazo ML, González Gancedo P, Martínez-Piñeiro JA, de La Peña JJ.
    Eur Urol; 2000 Mar; 37(3):289-96. PubMed ID: 10720854
    [Abstract] [Full Text] [Related]

  • 17. Use of percent free prostate-specific antigen density to improve the specificity for detecting prostate cancer in patients with normal rectal examinations and intermediate prostate-specific antigen levels.
    Baltaci S, Aksoy H, Türkölmez K, Elhan AH, Ozden E, Göğüş O.
    Urol Int; 2003 Mar; 70(1):36-41. PubMed ID: 12566813
    [Abstract] [Full Text] [Related]

  • 18. [Real-time elastography in the diagnosis of prostate cancer: personal experience].
    Romagnoli A, Autieri G, Centrella D, Gastaldi C, Pedaci G, Rivolta L, Pozzi E, Anghileri A, Cerabino M, Bianchi CM, Roggia A.
    Urologia; 2010 Mar; 77(4):248-53. PubMed ID: 21234867
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Complexed prostate-specific antigen, complexed prostate-specific antigen density of total and transition zone, complexed/total prostate-specific antigen ratio, free-to-total prostate-specific antigen ratio, density of total and transition zone prostate-specific antigen: results of the prospective multicenter European trial.
    Djavan B, Remzi M, Zlotta AR, Ravery V, Hammerer P, Reissigl A, Dobronski P, Kaisary A, Marberger M.
    Urology; 2002 Oct; 60(4 Suppl 1):4-9. PubMed ID: 12384156
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.